AnaptysBio shares are trading lower. UBS maintained a Hold rating on the stock.
Portfolio Pulse from Benzinga Newsdesk
AnaptysBio shares are trading lower following UBS's decision to maintain a Hold rating on the stock.
October 30, 2024 | 3:17 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AnaptysBio shares are experiencing a decline after UBS decided to maintain its Hold rating on the stock.
The Hold rating from UBS suggests a neutral stance, which may not inspire confidence among investors, leading to a short-term decline in AnaptysBio's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100